A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

Pfizer

Status and phase

Completed

Phase 2

Phase 1

Conditions

Lung Neoplasms

Treatments

Drug: CP-547,632

Study type

Interventional

Funder types

Industry

Identifiers

NCT00074854

A3521002

Details and patient eligibility

About

The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc).
Bidimensionally measurable disease >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan.

Exclusion criteria

No tumors in close proximity to major veins or arteries.
No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease.
No evidence or history brain metastases.